Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

T-DM1 demonstrates overall survival benefit in metastatic breast cancer: Next target, FDA approval

Written by | 3 Sep 2012

In news that is bound to excite breast cancer patients and investors, Genentech/Roche/Immunogen issued press releases on August 26, 2012, confirming that their drug-of-the-moment T-DM1 (trastuzumab emtansine) offers… read more.

EAHP 2012 Report – Report of plenary lecture – The evolution of cancer treatment

Written by | 3 Aug 2012

by Christine Clark – Changes in the diagnosis and treatment of cancer form the basis for future developments.  There have been many revolutions in medical science over the… read more.

Interdisciplinary care helps breast cancer prognosis

Written by | 31 Jul 2012

by Gary Finnegan – World Health Matters (Germany) – An interdisciplinary care model for breast cancer management has grown in popularity in recent years and evidence suggests the… read more.

Little benefit in imaging tests for women with breast pain

Written by | 14 Jun 2012

by Bruce Sylvester – Women with breast pain who undergo extra-routine mammograms, MRIs or ultrasounds as part of breast pain evaluation derive no diagnostic or therapeutic benefit, researchers… read more.

US health care: doing less with more

Written by | 14 Jun 2012

World Health Matters (U.S.A.) – by Gary Finnegan – The United States is paying far more for health services than 12 comparable industrialised nations but the quality of… read more.

Report from Cork branch Irish Association for Nurses in Oncology meeting 21st April 2012

Written by | 12 Jun 2012

In order to promote the ongoing education in cancer care which is one of the objectives of the association the Cork branch holds an annual education update. In… read more.

SABCS 2011 Report – The role of adjuvant bisphosphonates in breast cancer: The mist has started to clear

Written by | 14 May 2012

by Dr Sunil Upadhyay – The role of bisphosphonates in the management of breast cancer with bone metastases is well established. However, their benefit in the adjuvant setting… read more.

SABCS 2011 Report – Everolimus in management of tumour resistance in breast cancer

Written by | 14 May 2012

by Dr Sunil Upadhyay – The majority of breast cancer patients diagnosed with oestrogen receptor positive tumours respond well to endocrine therapy like tamoxifen and aromatase inhibitors, when… read more.

SABCS 2011 Report – Clarifying the risk of breast cancer in women with atypical breast lesions

Written by | 14 May 2012

by Dr Sunil Upadhyay – We know that atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in-situ (LCIS) and borderline DCIS/severe ADH are breast lesions which… read more.

SABCS 2011 Report – New standards in the management of HER2+ breast cancer tumours

Written by | 14 May 2012

by Dr Sunil Upadhyay – The San Antonio Breast Cancer Symposium 2011 was as exciting as ever with much new data and up-dates presented. Despite the ‘hot off… read more.

SABCS 2011 Report – Environmental and lifestyle influences on the development of breast cancer

Written by | 14 May 2012

by Dr Sunil Upadhyay – Breast cancer is one of the most common malignancies in women all over the world and its complex and multi-factorial aetiology remains unclear…. read more.

SABCS 2011 Report – Tumour markers for patient selection in treatment with VEGF inhibitors

Written by | 14 May 2012

by Dr Sunil Upadhyay – It is well known that HER2-positive marker positively regulates VEGF expression and VEGR levels correlate with HER2 over-expression. There is emerging evidence to… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.